Lan Le

664 total citations
17 papers, 238 citations indexed

About

Lan Le is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Lan Le has authored 17 papers receiving a total of 238 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Lan Le's work include Ferroptosis and cancer prognosis (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Lan Le is often cited by papers focused on Ferroptosis and cancer prognosis (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Lan Le collaborates with scholars based in United States, Japan and Canada. Lan Le's co-authors include Kazuaki Takabe, Yoshihisa Tokumaru, Masanori Oshi, Li Yan, Itaru Endo, Ryusei Matsuyama, Ankit Patel, Manabu Futamura, Takashi Ishikawa and Eriko Katsuta and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Lan Le

15 papers receiving 234 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lan Le United States 9 94 89 78 67 47 17 238
Yingjie Wu China 7 60 0.6× 40 0.4× 31 0.4× 33 0.5× 25 0.5× 13 214
Lishu Zhao China 10 74 0.8× 109 1.2× 87 1.1× 26 0.4× 40 0.9× 30 235
Qiaoqiao Huang China 9 150 1.6× 26 0.3× 48 0.6× 107 1.6× 34 0.7× 12 280
Han Han China 8 67 0.7× 55 0.6× 180 2.3× 40 0.6× 44 0.9× 18 288
Bambang Hermani Indonesia 7 58 0.6× 142 1.6× 68 0.9× 43 0.6× 17 0.4× 13 338
Sangeetha Prabhakaran United States 8 80 0.9× 255 2.9× 65 0.8× 46 0.7× 195 4.1× 20 425
Shu‐Yung Lin Taiwan 10 54 0.6× 95 1.1× 74 0.9× 25 0.4× 72 1.5× 24 300
Talal El Zarif United States 8 53 0.6× 54 0.6× 45 0.6× 33 0.5× 6 0.1× 28 163
Juan José Nieto‐Fontarigo Spain 13 52 0.6× 34 0.4× 141 1.8× 25 0.4× 71 1.5× 30 352
Shôichi Ihara Japan 8 43 0.5× 63 0.7× 69 0.9× 15 0.2× 21 0.4× 20 148

Countries citing papers authored by Lan Le

Since Specialization
Citations

This map shows the geographic impact of Lan Le's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lan Le with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lan Le more than expected).

Fields of papers citing papers by Lan Le

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lan Le. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lan Le. The network helps show where Lan Le may publish in the future.

Co-authorship network of co-authors of Lan Le

This figure shows the co-authorship network connecting the top 25 collaborators of Lan Le. A scholar is included among the top collaborators of Lan Le based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lan Le. Lan Le is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Kamath, Vidyulata, Lisa R. Yanek, Karin J. Neufeld, et al.. (2024). Poor olfaction prior to cardiac surgery: Association with cognition, plasma neurofilament light, and post‐operative delirium. International Journal of Geriatric Psychiatry. 39(2). e6066–e6066. 6 indexed citations
2.
Le, Lan. (2024). Uncovering Import Document Fraud: Leveraging the Deep Learning Approach. Global Trade and Customs Journal. 20(Issue 1). 3–10. 3 indexed citations
3.
Le, Lan, Sajesh K. Veettil, Richard E. Nelson, et al.. (2023). Disparities in COVID-19 related outcomes in the United States by race and ethnicity pre-vaccination era: an umbrella review of meta-analyses. Frontiers in Public Health. 11. 1206988–1206988. 8 indexed citations
4.
Brown, Charles H., Lisa R. Yanek, Kaushik Mandal, et al.. (2023). Association of perioperative plasma concentration of neurofilament light with delirium after cardiac surgery: a nested observational study. British Journal of Anaesthesia. 132(2). 312–319. 9 indexed citations
5.
Oshi, Masanori, Ankit Patel, Rongrong Wu, et al.. (2022). Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer. npj Breast Cancer. 8(1). 92–92. 21 indexed citations
6.
Le, Lan, et al.. (2022). Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies. Value in Health. 26(4). 598–611. 17 indexed citations
7.
Le, Lan, Yoshihisa Tokumaru, Masanori Oshi, et al.. (2021). Th2 cell infiltrations predict neoadjuvant chemotherapy response of estrogen receptor-positive breast cancer. Gland Surgery. 10(1). 154–165. 33 indexed citations
8.
Oshi, Masanori, Lan Le, Yoshihisa Tokumaru, et al.. (2021). Abundance of Microvascular Endothelial Cells Is Associated with Response to Chemotherapy and Prognosis in Colorectal Cancer. Cancers. 13(6). 1477–1477. 23 indexed citations
9.
Oshi, Masanori, Ankit Patel, Lan Le, et al.. (2021). G2M checkpoint pathway alone is associated with drug response and survival among cell proliferation-related pathways in pancreatic cancer.. PubMed. 11(6). 3070–3084. 45 indexed citations
11.
Oshi, Masanori, Lan Le, Yoshihisa Tokumaru, et al.. (2021). G2M checkpoint signaling among six-cell proliferation-related pathway as a biomarker for prediction and prognosis in pancreatic cancer.. Journal of Clinical Oncology. 39(15_suppl). e16264–e16264.
12.
Oshi, Masanori, Lan Le, Fernando A. Angarita, et al.. (2021). Association of allograft rejection response score with biological cancer aggressiveness and with better survival in triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 39(15_suppl). 561–561. 2 indexed citations
13.
Tokumaru, Yoshihisa, Eriko Katsuta, Masanori Oshi, et al.. (2020). High Expression of miR-34a Associated with Less Aggressive Cancer Biology but Not with Survival in Breast Cancer. International Journal of Molecular Sciences. 21(9). 3045–3045. 38 indexed citations
14.
Tokumaru, Yoshihisa, Lan Le, Masanori Oshi, et al.. (2020). Association of Th2 high tumors with aggressive features of breast cancer.. Journal of Clinical Oncology. 38(15_suppl). e12584–e12584. 13 indexed citations
15.
Chen, Li‐Chia, Lan Le, Mike Sung, et al.. (2019). EP1.16-05 Real World Outcomes of Advanced NSCLC Patients with Liver Metastases. Journal of Thoracic Oncology. 14(10). S1066–S1066. 2 indexed citations
16.
Le, Lan, et al.. (2018). Neuroleptic Prescribing and Monitoring Practices in Pediatric Inpatient Medical and Psychiatric Settings. Hospital Pediatrics. 8(7). 410–418. 5 indexed citations
17.
Sridhar, Srikala S., Walter M. Stadler, Lan Le, et al.. (2005). Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium. Journal of Clinical Oncology. 23(16_suppl). 4677–4677. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026